Tags

Type your tag names separated by a space and hit enter

Echinacea-associated anaphylaxis.
Med J Aust 1998; 168(4):170-1MJ

Abstract

A woman with atopy experienced anaphylaxis after taking, among other dietary supplements, a commercial extract of echinacea. Hypersensitivity was confirmed by skinprick and RAST testing. Regular ingestion of echinacea by up to 5% of surveyed patients with atopy, combined with detection of echinacea-binding IgE in atopic subjects (19% by skin testing; 20% with moderate to strong reactivity by RAST testing), raises the possibility of severe allergic reactions, even with first-time use, due to cross-reactivity with other structurally similar allergens. Patients with atopy should be cautioned about the risk of developing life-threatening reactions to complementary medicines, including echinacea.

Authors+Show Affiliations

John James Medical Centre, Deakin. rmullins@racp.edu.au

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

9507713

Citation

Mullins, R J.. "Echinacea-associated Anaphylaxis." The Medical Journal of Australia, vol. 168, no. 4, 1998, pp. 170-1.
Mullins RJ. Echinacea-associated anaphylaxis. Med J Aust. 1998;168(4):170-1.
Mullins, R. J. (1998). Echinacea-associated anaphylaxis. The Medical Journal of Australia, 168(4), pp. 170-1.
Mullins RJ. Echinacea-associated Anaphylaxis. Med J Aust. 1998 Feb 16;168(4):170-1. PubMed PMID: 9507713.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Echinacea-associated anaphylaxis. A1 - Mullins,R J, PY - 1998/3/21/pubmed PY - 1998/3/21/medline PY - 1998/3/21/entrez SP - 170 EP - 1 JF - The Medical journal of Australia JO - Med. J. Aust. VL - 168 IS - 4 N2 - A woman with atopy experienced anaphylaxis after taking, among other dietary supplements, a commercial extract of echinacea. Hypersensitivity was confirmed by skinprick and RAST testing. Regular ingestion of echinacea by up to 5% of surveyed patients with atopy, combined with detection of echinacea-binding IgE in atopic subjects (19% by skin testing; 20% with moderate to strong reactivity by RAST testing), raises the possibility of severe allergic reactions, even with first-time use, due to cross-reactivity with other structurally similar allergens. Patients with atopy should be cautioned about the risk of developing life-threatening reactions to complementary medicines, including echinacea. SN - 0025-729X UR - http://www.unboundmedicine.com/medline/citation/9507713/full_citation L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0025-729X&date=1998&volume=168&issue=4&spage=170 DB - PRIME DP - Unbound Medicine ER -